This website is intended for healthcare professionals only

Trending Topic

Glowing thyroid gland is highlighted within a digital rendering of the human neck anatomy.
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Faris F Halaseh, Suraj M Rajan, Nadia Nash

Hypothyroidism, defined as a state of deficient thyroid hormone production characterized biochemically by elevated thyroid-stimulating hormone with low or inappropriately normal circulating thyroxine, is a common endocrine disorder affecting 4–5% of the population of the USA.1,2 Pericardial effusion occurs in 30–80% of patients with severe hypothyroidism or myxedema, although estimates vary across studies.3–6 While most […]

Erwan Donal, ESC 2022: The TriClip bRIGHT study for symptomatic patients with severe tricuspid regurgitation

8 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 6th 2022

The bRIGHT study aimed to evaluate the safety and effectiveness of the TriClip device in symptomatic patients with severe tricuspid regurgitation. In this touchCARDIO interview, we speak with Professor Erwan Donal (University Hospital of Rennes, Rennes, France) to discuss tricuspid transcatherter edge-to-edge repair, the difficulty in patient selection and the purpose and conclusions of the TriClip bRIGHT study.

The abstract entitled ‘Impact of coaptation gap location on procedural strategy and outcomes following tricuspid transcatheter edge-to-edge repair: insights from the TriClip bRIGHT study’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.

Questions:

  1. Could you give us a brief overview of tricuspid transcatherter edge-to-edge repair and its clinical impact? (0:40)
  2. What are the challenges of patient selection for this procedure? (2:03)
  3. What were the objectives of the TriClip bRIGHT study? (3:27)
  4. How did procedural and short-term outcomes vary according to coaptation gap location? (4:23)
  5. What were the conclusions of the investigators? (5:49)

Disclosures: Erwan Donal is on the advisory board for Abbott; GE healthcare and Pfizer and has received honoraria from Alnylam, Bristol Myer Squibb and Pfizer. CHU Rennes has a research contract with Abbott structural.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ESC 2022

Access more content on Devices here and Interventional Cardiology here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup